Across 955 individuals drawn from 28 independent cohorts spanning 24 countries, a metagenomic meta-analysis pinpointed 16 microbial species that collectively discriminate frailty from robust aging. Shannon diversity dropped sharply at the robust-to-pre-frail transition (p = 0.0006) — before clinical disease manifests. A Random Forest model anchored by Collinsella massiliensis achieved an AUC of 0.7572 via leave-one-study-out cross-validation. Core symbionts like Coprococcus eutactus progressively eroded while pathobionts like Enterococcus gallinarum expanded. Crucially, these shifts held in a 499-person healthy sub-cohort, ruling out disease-related confounding.
This work reframes the gut microbiome not merely as a metabolic bystander but as an early-warning system for systemic physiological decline. The finding that microbial restructuring precedes diagnosable frailty is particularly significant: it opens a window for intervention before the cascade of sarcopenia, immune dysregulation, and cognitive decline becomes entrenched. Prior frailty biomarker research has leaned heavily on inflammatory markers like IL-6 or CRP, which appear later in the decline trajectory. A stool-based 16-species panel is non-invasive, scalable, and potentially modifiable through diet or targeted probiotics — advantages no blood biomarker offers. Limitations are real: the AUC of 0.757 is promising but not yet clinically actionable on its own, the cohorts skew European and East Asian limiting global generalizability, and causality remains unestablished. Still, for a heterogeneous, multi-country dataset, the cross-population consistency is genuinely striking — an incremental but meaningfully directional advance toward precision geriatric screening.
